FINANCIAL POST
The partnership signals the first deal between a major pharmaceutical company and a Canadian cannabis producer.
FINANCIAL POST
The partnership signals the first deal between a major pharmaceutical company and a Canadian cannabis producer.
THE GLOBE AND MAIL
Tilray has raised $60-million to expand its growing capacity in Canada and Europe and to push its brand of medical cannabis products into a handful of new countries.
CBC NEWS
Following Germany, several other European countries, including Greece, Italy, Poland and the Czech Republic, passed new medical cannabis laws. That's led Tilray to begin construction of a $30-million production facility in Portugal to help supply the growing market.
CBC NEWS
Tilray Chief Executive Officer Brendan Kennedy discusses Tilray's Portugal expansion with CBC Business News.
THE NEW YORK TIMES
Tilray CEO Brendan Kennedy shared his insights about Canada's history-making effort to legalize and regulate adult-use cannabis.
PBS NEWSHOUR
PBS speaks to neuroscientist Catherine Jacobson, who heads clinical research for Tilray, about how the company is trying to turn cannabis into conventional medicine.
BUSINESS NEWS NETWORK
Tilray, a Canadian cannabis producer, recently announced that it received approval to ship two varieties of liquid capsules to Croatia. Brendan Kennedy, Global President with Tilray says that Europe presents a good growth opportunity for Tilray.
CBC NEWS
Canadian cannabis producer Tilray is placing its bets on budding demand from markets overseas as it begins shipping medical marijuana products to Croatia.
VICE NEWS
Tilray, based in British Columbia and one of the companies licensed by Canada's federal health ministry to produce and distribute medical cannabis, was recently granted an export permit. It's believed to be the first time a North American company has legally exported cannabis to the EU for commercial medical use.
WHAT SHE SAID RADIO (SIRIUSXM)
There are still far too many myths and misconceptions surrounding medical cannabis. On Tuesday, Dr. Catherine Jacobson, the Director of Clinical Research at Tilray, appeared on What She Said Radio to debunk those myths and answer some frequently asked questions.
CTV VANCOUVER ISLAND
Tilray, one of Canada's largest medical marijuana producers, has opened the doors of its 65,000-square-foot, $30-million Nanaimo facility to give a rare glimpse of its production process. Company CEO Greg Engel answers five questions about the facility, its employees, legalization, and lessons for the industry.
WASHINGTON POST
Brendan Kennedy, president of Privateer Holdings of Seattle, welcomed the Canadian announcement. His company owns Tilray, a medicinal marijuana facility in British Columbia, and he is looking to build a facility that would supply the market for recreational marijuana in Canada.
THE GUARDIAN
As a mother, I am furious that the federal government has discouraged research into these potentially life-saving therapies for years by restricting clinical research. As a scientist, I decry the federal government for interfering with scientific freedom.
NATIONAL POST
These seismic global shifts in perception and policy have a deeply personal significance for me. As a scientist and director of clinical research at Tilray, one of Canada’s largest producers of medical cannabis, I welcome policies that open the doors for ground-breaking and potentially life-saving research.
NEWS.COM.AU
Earlier this month, the global president of Canadian firm Tilray predicted medical marijuana had the potential to be a billion-dollar industry in Australia and create thousands of skilled jobs.
ABC NEWS AUSTRALIA
Medical cannabis is a US$10b market that will grow to $100b over next 3 to 5 years, that's according to Brendan Kennedy, global president of Tilray, one of the largest producers of the product. Tilray is owned by US private equity firm Privateer Holdings. Last week the Australian senate passed legislation to allow the growing of medical cannabis.
AUSTRALIAN BROADCASTING CORPORATION
The largest clinical trial of its kind, testing medicinal cannabis to treat chemotherapy patients suffering from nausea, has been announced by New South Wales Premier Mike Baird. About 330 patients are expected to take part in the clinical trial which will use a cannabis-derived tablet manufactured by Canadian company Tilray.
SYDNEY MORNING HERALD
A Canadian pharmaceutical company, Tilray, will supply the trial with specially-prepared tablets that contain marijuana extracts that maximise the drug's anti-nausea properties and minimise its psychoactive effects.
THE GLOBE AND MAIL
Philippe Lucas, executive director of the council, said he met with a policy adviser to Finance Minister Bill Morneau during prebudget consultations last week. His group represents Tilray, Peace Naturals and Delta 9 Bio-Tech, which are among about two dozen commercial producers licensed to ship medical marijuana to patients through the mail.
CALGARY HERALD
The operation on Vancouver Island has been shipping BC-grown medical marijuana to Canadian patients for whom it has been prescribed since April 28, 2014.